Inhibrx (INBX) News Today $24.97 -0.39 (-1.54%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$23.83▼$25.5750-Day Range$14.50▼$25.5652-Week Range$14.31▼$30.71Volume348,372 shsAverage Volume407,995 shsMarket Capitalization$1.18 billionP/E RatioN/ADividend YieldN/APrice Target$36.50 HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineInhibrx Inc Ordinary Shares INBXmorningstar.com - December 9 at 12:42 PMContrasting Cullinan Oncology (NASDAQ:CGEM) & Inhibrx (NASDAQ:INBX)americanbankingnews.com - December 7 at 3:46 AMInhibrx, Inc. (NASDAQ:INBX) Short Interest Up 5.4% in Novemberamericanbankingnews.com - December 4 at 2:40 AMInhibrx Inc Ordinary Sharesmorningstar.com - December 2 at 12:50 PMInhibrx posts Q3 resultsmsn.com - November 10 at 1:16 PMInhibrx, Inc.: Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlightsfinanznachrichten.de - November 10 at 8:16 AMInhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlightsfinance.yahoo.com - November 9 at 8:10 PMInhibrx reports initial Phase I Ewing sarcoma trial datamsn.com - November 4 at 7:27 AMInhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcomafinance.yahoo.com - November 2 at 1:13 PMInhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canadafinance.yahoo.com - September 19 at 6:29 PMCitigroup Inc. Buys 37,822 Shares of Inhibrx, Inc. (NASDAQ:INBX)marketbeat.com - September 6 at 4:41 AMInhibrx Shares Rise 15% After Private Placement Financingmarketwatch.com - August 29 at 3:34 PMInhibrx Announces $200 Million Private Placement Financingfinance.yahoo.com - August 29 at 10:09 AMJMP Securities Maintains Outperform Rating for Inhibrx: Here's What You Need To Knowmarkets.businessinsider.com - August 23 at 4:06 PMJMP Securities Maintains Inhibrx (INBX) Outperform Recommendationnasdaq.com - August 23 at 9:45 AMJMP Securities Reaffirms Their Buy Rating on Inhibrx (INBX)markets.businessinsider.com - August 23 at 4:45 AMInhibrx, Inc. (NASDAQ:INBX) Shares Sold by Barclays PLCmarketbeat.com - August 21 at 4:35 AMInhibrx, Inc. (NASDAQ:INBX) Forecasted to Post Q3 2023 Earnings of ($0.96) Per Sharemarketbeat.com - August 21 at 1:52 AMInhibrx: INBRX-101 Developments Constructive, Market-Generated Data Not So Muchmsn.com - August 17 at 9:20 PMLifeSci Capital Sticks to Their Buy Rating for Inhibrx (INBX)markets.businessinsider.com - August 16 at 6:37 PMInhibrx's (INBX) "Outperform" Rating Reaffirmed at Lifesci Capitalmarketbeat.com - August 11 at 11:27 AMInhibrx, Inc. Expected to Post FY2023 Earnings of ($3.99) Per Share (NASDAQ:INBX)marketbeat.com - August 11 at 10:00 AMInhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlightsfinance.yahoo.com - August 8 at 11:11 AMInhibrx, Inc. (NASDAQ:INBX) Stock Position Lowered by Los Angeles Capital Management LLCmarketbeat.com - August 8 at 5:49 AMJump Financial LLC Decreases Holdings in Inhibrx, Inc. (NASDAQ:INBX)marketbeat.com - August 7 at 7:34 AMVirtu Financial LLC Acquires Shares of 10,369 Inhibrx, Inc. (NASDAQ:INBX)marketbeat.com - July 28 at 5:47 AMTheft in open court: How a fight over lifesaving drugs led to accusations of brazen industrial espionagemarketwatch.com - June 27 at 1:19 PMGSA Capital Partners LLP Takes Position in Inhibrx, Inc. (NASDAQ:INBX)marketbeat.com - June 7 at 7:27 AMInhibrx, Inc. (NASDAQ:INBX) Shares Purchased by UBS Group AGmarketbeat.com - June 5 at 4:37 AMInhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiencyfinance.yahoo.com - May 30 at 1:31 PMInhibrx, Inc. (NASDAQ:INBX) Stake Decreased by Citigroup Inc.marketbeat.com - May 25 at 5:35 AMJMP Securities Reiterates Inhibrx (INBX) Market Outperform Recommendationmsn.com - May 11 at 9:18 PMInhibrx Inc.: Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlightsfinanznachrichten.de - May 9 at 1:49 PMInhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlightsfinance.yahoo.com - May 8 at 8:47 PMInhibrx, Inc. (INBX) Reports Q1 Loss, Lags Revenue Estimatesfinance.yahoo.com - May 8 at 8:47 PMStrength Seen in Inhibrx, Inc. (INBX): Can Its 9.9% Jump Turn into More Strength?msn.com - May 4 at 4:22 AMLos Angeles Capital Management LLC Sells 19,631 Shares of Inhibrx, Inc. (NASDAQ:INBX)marketbeat.com - May 3 at 5:26 AMINBX Makes Bullish Cross Above Critical Moving Averagenasdaq.com - May 1 at 11:26 PMInhibrx, Inc. Expected to Earn FY2023 Earnings of ($3.99) Per Share (NASDAQ:INBX)marketbeat.com - May 1 at 3:21 AMInhibrx Resumes Patient Enrollment In INBRX-109 Studies In Cancer Patientsmsn.com - April 26 at 8:26 PMInhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trialsfinance.yahoo.com - April 26 at 9:50 AMInhibrx: Undercovered Company With Good Potentialseekingalpha.com - April 13 at 11:12 AMThe past year for Inhibrx (NASDAQ:INBX) investors has not been profitablefinance.yahoo.com - March 23 at 8:03 AMInhibrx Stock (NASDAQ:INBX), Analyst Ratings, Price Targets, Predictionsbenzinga.com - March 13 at 5:39 AMInhibrx Inc.: Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Resultsfinanznachrichten.de - March 7 at 6:21 AMInhibrx GAAP EPS of -$0.95 misses by $0.16, revenue of $0.27M misses by $0.52Mmsn.com - March 6 at 8:21 PMInhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Resultsfinance.yahoo.com - March 6 at 8:21 PMInhibrx, Inc. (INBX) Reports Q4 Loss, Misses Revenue Estimatesfinance.yahoo.com - March 6 at 8:21 PMCubist Systematic Strategies LLC Has $1.38 Million Stake in Inhibrx, Inc. (NASDAQ:INBX)marketbeat.com - February 10 at 1:17 PMSG Americas Securities LLC Takes Position in Inhibrx, Inc. (NASDAQ:INBX)marketbeat.com - February 8 at 4:13 AM Get Inhibrx News Delivered to You Automatically Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter. Email Address INBX Media Mentions By Week INBX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INBX News Sentiment▼0.140.52▲Average Medical News Sentiment INBX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INBX Articles This Week▼41▲INBX Articles Average Week Get Inhibrx News Delivered to You Automatically Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Apogee Therapeutics News Scholar Rock News Kymera Therapeutics News Vir Biotechnology News BioCryst Pharmaceuticals News ADMA Biologics News REGENXBIO News Talaris Therapeutics News Merus News Valneva News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:INBX) was last updated on 12/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibrx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.